New hope for rare lung condition: experimental drug shows promise

NCT ID NCT00993408

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 33 times

Summary

This study tested an experimental drug called ACT-293987 in 43 adults with pulmonary arterial hypertension (PAH), a serious condition where high blood pressure damages the arteries in the lungs. Participants first received a single dose to measure immediate effects on blood flow, then took the drug or a placebo twice daily for 21 weeks. The goal was to see if the drug improves blood vessel function and exercise ability, while checking for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Department of Respiratory Medicine, Hannover Medical School

    Hanover, 30625, Germany

  • Gasthuisberg University Hospital, Pneumology

    Leuven, 3000, Belgium

  • Hammersmith Hospital

    London, W12 0HS, United Kingdom

  • Hopital Antoine Beclere, Pneumologie

    Paris, France

  • Hospital Sant'Orsola Malpighi, Cardiology's Department

    Bologna, 40138, Italy

  • Instytut Gruzilcy i Chorob Pluc, Klinika Chorob Wewnetrznych Klatki Piersiowej

    Warsaw, 01-138, Poland

  • Medizinische Universitat Wien, Universitatsklinik fur Innere Medizin II, Kardiologie

    Vienna, 1090, Austria

  • Semmelweis University, Clinic of Pulmonology

    Budapest, H-1125, Hungary

Conditions

Explore the condition pages connected to this study.